ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 62 filers reported holding ARBUTUS BIOPHARMA CORP in Q2 2019. The put-call ratio across all filers is 1.63 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1 | 0.0% | 395 | 0.0% | 0.00% | – |
| Q2 2023 | $1 | 0.0% | 395 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | 0.0% | 395 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | -99.9% | 395 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 395 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 395 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | -50.0% | 395 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | +100.0% | 395 | +146.9% | 0.00% | – |
| Q3 2021 | $1,000 | – | 160 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 160 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 160 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | – | 160 | -47.4% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 304 | 0.0% | 0.00% | – |
| Q2 2019 | $1,000 | 0.0% | 304 | 0.0% | 0.00% | – |
| Q1 2019 | $1,000 | 0.0% | 304 | 0.0% | 0.00% | – |
| Q4 2018 | $1,000 | -66.7% | 304 | 0.0% | 0.00% | – |
| Q3 2018 | $3,000 | +50.0% | 304 | 0.0% | 0.00% | – |
| Q2 2018 | $2,000 | 0.0% | 304 | 0.0% | 0.00% | – |
| Q1 2018 | $2,000 | – | 304 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
| RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
| APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
| Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
| COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
| Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
| Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
| Shay Capital LLC | 60,000 | $257,000 | 0.03% |
| Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |